Valuation: Zai Lab Limited

Market Cap 2.16B 1.9B 1.76B 1.62B 3.04B 208B 3.09B 20.95B 8.18B 102B 8.11B 7.93B 353B P/E 2026 *
-8.68x
P/E 2027 * -10.3x
Enterprise Value 1.72B 1.51B 1.4B 1.29B 2.42B 165B 2.45B 16.65B 6.5B 81.26B 6.44B 6.3B 281B EV / Sales 2026 *
3.83x
EV / Sales 2027 * 2.98x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.16B
+0.63%-3.06%+16.18%-9.78% 66.74B
+1.23%+2.80%+37.51%+202.14% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.63%-57.10% 38.25B
+0.78%-1.84%+52.49%-27.01% 29.85B
+0.84%+0.36%+66.93%+85.42% 23.51B
-5.17%-12.54%+58.98%-56.04% 21.45B
-1.21%+1.12%+1.98%+170.93% 19.97B
-0.22%-0.95%+61.97%+123.78% 16.38B
Average +1.16%-1.00%+32.25%+53.79% 35.29B
Weighted average by Cap. +1.80%-0.11%+27.80%+49.98%

Financials

2026 *2027 *
Net sales 449M 394M 366M 336M 632M 43.21B 642M 4.35B 1.7B 21.24B 1.68B 1.65B 73.45B 596M 523M 486M 446M 839M 57.35B 852M 5.78B 2.26B 28.2B 2.24B 2.19B 97.49B
Net income -241M -212M -197M -181M -339M -23.2B -344M -2.34B -913M -11.41B -904M -885M -39.43B -156M -137M -128M -117M -220M -15.07B -224M -1.52B -593M -7.41B -587M -575M -25.61B
Net Debt -443M -389M -362M -332M -624M -42.67B -634M -4.3B -1.68B -20.98B -1.66B -1.63B -72.54B -387M -340M -316M -290M -545M -37.29B -554M -3.76B -1.47B -18.33B -1.45B -1.42B -63.38B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A